Compare AbCellera Biologics Inc (ABCL) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs PPG Industries, Inc. — how do they compare? AbCellera Biologics Inc trades at $9.14 (market cap $2.85B), while PPG Industries, Inc. trades at $115.82 (market cap $25.67B). The key difference: PPG Industries, Inc. is far larger — about 9× AbCellera Biologics Inc's market cap, and PPG Industries, Inc. pays a 2.56% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PPG | |
|---|---|---|
Market Cap | $2.85B | $25.67B |
Sector | Health | Basic Materials |
52-Week High | $9.76 | $131.56 |
52-Week Low | $2.78 | $94.34 |
Enterprise Value | $2.45B | $31.54B |
Dividend Yield | — | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
PPG Industries trades at $119.72, up 2.19% on the day, with a bullish technical outlook supported by moving averages. The company reported Q2 2026 sales growth of 7% year-over-year but missed EPS estimates. Recent dividend hikes and strong cash flow highlight financial health, while valuation ratios like a P/E of 17.18 suggest reasonable pricing. Analyst consensus is positive with a $129.17 price target.
Outlook remains favorable due to consistent dividend growth and operational strength, though risks include cost pressures and mixed earnings performance. The stock offers a balanced opportunity with upside potential from analyst targets, but investors should monitor margin trends and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
